Layered IP Protection
TP-317 is protected by composition of matter patents in the U.S. and internationally.
TP-317 Stability Breakthrough
RVE1 CHALLENGE
RvE1, a potent lipid mediator, is extremely vulnerable to oxidative degradation ― impeding clinical development.
TP-317 SOLUTION
A novel small molecule of RvE1 that maintains stability as an oral formulation where previous attempts failed.
PATH FORWARD
TP-317 enables scalable manufacturing, extended shelf-life, predictable drug delivery, and IP protection to 2048.
Oral TP-317 Performance in Phase 1a Guides Dose Selection for Phase 1b
Oral Formulation
Releases RvE1 in the upper intestine
for systemic absorption
Safety & PK
Well tolerated with
dose-proportional pharmacokinetics
Target Coverage
RvE1 blood levels sufficient to
activate BLT1 at all doses
Layered IP Protection
TP-317 is protected by composition of matter patents in the U.S. and internationally.
Multiple Patent Families
Family #1: Granted: US, EU, Asia
Family #2: Granted: US │ Pending: ROW
Manufacturing Trade Secrets
Strong barriers to generic entry